Skip to main content
ZVRA
NASDAQ Life Sciences

Zevra 10-Q: Q3 Net Income $19.2M, Nine-Month Net Income $65.9M, $270.9M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$10.5
Mkt Cap
$609.278M
52W Low
$8.01
52W High
$15.035
52W Position info
31% above low
Off High info
30% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ZVRA sits 31% above its 52-week low of $8.01.

Summary

Zevra reported Q3 2026 net income of $19.2 million on $37.8 million of revenue and held $270.9 million in cash and investments with no debt. Its European arimoclomol application remains in re-examination after a negative CHMP opinion.


Key Events · Earnings and Guidance · ZVRA

  • Q3 Revenue $37.8M, Net Income $19.2M

    Third-quarter revenue rose to $37.8 million from $26.1 million a year earlier, with MIPLYFFA sales of $34.0 million versus $22.4 million. Net income was $19.2 million, or $0.26 per diluted share.

  • Nine-Month Net Income $65.9M

    Nine-month net income of $65.9 million included a $43.3 million net gain on the Commave Settlement Agreement, under which Commave paid $50.0 million for the SDX portfolio assets and the AZSTARYS license was terminated.

  • Cash $270.9M, Debt Fully Repaid

    Cash, cash equivalents and investments totaled $270.9 million at September 30, 2026, and the $63.1 million term loan was repaid in full on March 12, 2026, leaving no long-term debt. Management says this funds planned requirements for at least the next twelve months.

  • European Arimoclomol Opinion Negative

    The CHMP adopted a negative opinion on the arimoclomol MAA in July 2026; Zevra has requested a re-examination. A $4.0 million regulatory milestone to XOMA is tied to E.U. approval.


Analysis · ZVRA · Life Sciences

The headline numbers show a sharp swing: $19.2 million of net income on $37.8 million of revenue in the third quarter, and $65.9 million of net income for the first nine months of 2026, versus a prior-year loss. MIPLYFFA sales drove the turn, aided by a $43.3 million gain on the Commave settlement. Yet the balance sheet is the real story. Cash and investments stood at $270.9 million with no debt after the March repayment of the $63.1 million term loan, which management says funds planned requirements for at least the next twelve months. Against that, the European arimoclomol application took a negative CHMP opinion in July 2026 and is in re-examination, and OLPRUVA is being scaled back while strategic alternatives are weighed. The growth case now rests almost entirely on MIPLYFFA in the U.S.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZVRA was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $609.3M. The 52-week trading range was $8.01 to $15.04. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZVRA - Latest Insights

ZVRA
Nov 13, 2026, 6:26 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.10
Real-time Price: $9.42 info
Change: -$0.680 (-7%) info
Market Cap: $559.343M info
ZVRA
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.26
Real-time Price: $9.42 info
Change: -$0.840 (-8%) info
Market Cap: $559.343M info
ZVRA
Aug 05, 2026, 5:19 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.50
Real-time Price: $9.42 info
Change: -$1.08 (-10%) info
Market Cap: $559.343M info
ZVRA
Aug 05, 2026, 5:10 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $10.60
Real-time Price: $9.42 info
Change: -$1.18 (-11%) info
Market Cap: $559.343M info
ZVRA
Jun 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.42
Real-time Price: $9.42 info
Change: -$3.00 (-24%) info
Market Cap: $559.343M info